Semaglutide acetate (NNC-0113-0217; NNC0113-0217), the acetic acid salt form of semaglutide (Ozempic), is a human glucagon-like peptide-1 (GLP-1) receptor agonist with longer duration of antidiabetic action. As of December 2017, Semaglutide was approved by FDA to improve glycemic control in adults with type 2 diabetes mellitus.

纯度：≥98%